Right Colonic Reservoir with Submucosally Embedded Tapered lleum – ‘Tiflis Pouch’

1997 ◽  
Vol 59 (2) ◽  
pp. 113-118 ◽  
Author(s):  
Zaza Chanturaia ◽  
Ambrosi Pertia ◽  
George Managadze ◽  
George Khvadagiani ◽  
Temuri Chigogidze ◽  
...  
Keyword(s):  
Colonic Reservoir

Laparoscopic-assisted bowel resection with construction of a colonic reservoir for cavernous hemangioma of the rectum: report of two cases

2011 ◽  
Vol 15 (2) ◽  
pp. 205-207 ◽  
Author(s):  
R. F. Leal ◽  
M. de Lourdes Setsuko Ayrizono ◽  
P. V. Villalobos Tapia Silva ◽  
P. de Sene Portel Oliveira ◽  
J. J. Fagundes ◽  
...  
Keyword(s):  
Cavernous Hemangioma ◽  
Bowel Resection ◽  
Colonic Reservoir ◽  
Laparoscopic Assisted

Ileal Cecal Colonic Reservoir

2009 ◽  
pp. 538-541
Author(s):  
Frank Hinman ◽  
Laurence S. Baskin
Keyword(s):  
Colonic Reservoir

The Functional Outcomes of Coloanal and Low Colorectal Anastomoses with Reservoirs after Low Rectal Cancer Resections

2014 ◽  
Vol 80 (12) ◽  
pp. 1222-1229 ◽  
Author(s):  
FranÇ Ois Rubin ◽  
Richard Douard ◽  
Philippe Wind
Keyword(s):  
Rectal Cancer ◽  
Anastomotic Leakage ◽  
Functional Outcomes ◽  
Functional Results ◽  
Functional Impairments ◽  
Level Of Evidence ◽  
Anastomotic Complications ◽  
Colorectal Anastomoses ◽  
Anterior Rectal Resection ◽  
Colonic Reservoir

Nearly half of patients undergoing low anterior rectal cancer resection have a functional sequelae after straight coloanal or low colorectal anastomoses (SA), including low anterior rectal resection syndrome, which combines stool fragmentation, urge incontinence, and incontinence. SA are responsible for anastomotic leakage rates of 0 to 29.2 per cent. Adding a colonic reservoir improves the functional results while reducing anastomotic complications. These colonic reservoir techniques include the colonic J pouch (CJP), transverse coloplasty (TC), and side-to-end anastomosis (STEA) procedures. The aim of this literature review was to compare the functional outcomes of these three techniques from a high level of evidence. CJP with a 4- to 6-cm reservoir is a good surgical option because it reduces functional impairments during the first year, and probably up to 5 years, but is not always feasible. TC appears to perform as well as CJP, is achievable in over 95 per cent of patients, but still with some doubts about a higher anastomotic leakage rate and worse functional outcomes. STEA appears equivalent to CJP in terms of morbidity and even better functional outcomes. STEA, with a terminal side segment size of 3 cm, is feasible in the majority of nonobese patients, combines good functional results, has low anastomotic leakage rates, and is easy to complete.

Electrically stimulated colonic reservoir for total anorectal reconstruction

1995 ◽  
Vol 82 (10) ◽  
pp. 1321-1326 ◽  
Author(s):  
S. F. Hughes ◽  
S. M. Scott ◽  
M. A. Pilot ◽  
N. S. Williams
Keyword(s):  
Anorectal Reconstruction ◽  
Total Anorectal Reconstruction ◽  
Colonic Reservoir

Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4105-4105
Author(s):  
T. Dipetrillo ◽  
V. Pricolo ◽  
J. Lagares-Garcia ◽  
W. Sikov ◽  
M. Vrees ◽  
...  
Keyword(s):  
Clin Oncol ◽  
Annual Meeting ◽  
Conflict Of Interest ◽  
Fluid Collection ◽  
Gastrointestinal Toxicity ◽  
Wound Complications ◽  
Interest Policy ◽  
Modified Folfox6 ◽  
Colonic Reservoir ◽  
Grade 3

4105^ Background: This study evaluates induction bevacizumab and FOLFOX followed by concurrent chemoradiotherapy (CRT) with bevacizumab, weekly oxaliplatin, and continuous infusion 5-FU prior to surgical resection of newly-diagnosed Stage II or III rectal cancer. Methods: Eligible patients received one month of induction, biweekly bevacizumab (5mg/kg) and modified FOLFOX6. Patients then received 50.4Gy of radiation and concurrent bevacizumab (5 mg/kg on days 1, 15, and 29), oxaliplatin (50 mg/m2/week for 6 weeks), and 5-FU (200mg/m2/day) as a continuous IV infusion throughout radiation. Due to gastrointestinal toxicity, the oxaliplatin dose was reduced to 40 mg/m2/week. Resection was performed 4 to 8 weeks after the completion of CRT. Adjuvant chemotherapy was started after 4 but less than 12 weeks following surgical resection and consisted of 6 biweekly treatments of modified FOLFOX6 and bevacizumab. Results: Twenty-six eligible patients were treated. The median age was 50. One patient developed a grade 4 arrhythmia during induction chemotherapy and was removed from the study. Of the remaining 25 patients, there were no other grade 3 or 4 toxicities during induction FOLFOX/bevacizumab. Toxicity was more significant during chemoradiation. Any grade 3 toxicity was experienced by 19 of 25 (76%) patients. Grade 3 toxicities included diarrhea (40%), neutropenia (16%), pain (16%), fatigue (8%), nausea (8%), and radiation dermatitis (8%) and bleeding with menstruation (4%). Grade 4 toxicities included neutropenia (4%), sepsis (4%) and nausea/diarrhea (4%). Six of 25 resected patients (24%) had a complete pathologic response. Eight of 25 patients (32%) developed post-operative wound complications including infection/abscess (n=4), fistula (n=2), ischemic colonic reservoir (n=1) and sterile fluid collection (n=1). Nine of 25 (36%) patients developed postoperative wound complications including infection (n=4), delayed healing (n=3), leak/abscess (n=2), sterile fluid collection (n=2), ischemic colonic reservoir (n=1), and fistula (n=1). Conclusions: Concurrent oxaliplatin, bevacizumab, continuous infusion 5-FU and radiation causes significant gastrointestinal toxicity. The pathologic complete response rate of this regimen to similar to other fluorouracil based chemoradiaton regimens. The high incidence of post-operative wound complications is concerning and consistent with other reports utilizing bevacizumab prior to major surgical resections. [Table: see text] ASCO Conflict of Interest Policy and Exceptions In compliance with the guidelines established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519–521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the ASCO Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, consultant or advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520). The ASCO Conflict of Interest Policy disclosure requirements apply to all authors who submit abstracts to the Annual Meeting. For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract will be ineligible for placement in the 2009 Annual Meeting unless the ASCO Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research. NIH-sponsored trials are exempt from the Policy restrictions. Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings. For more information about the ASCO Conflict of Interest Policy and the exceptions process, please visit www.asco.org/conflictofinterest .

The transverse colonic reservoir: the Unicamp technique

2000 ◽  
Vol 85 (4) ◽  
pp. 486-489 ◽  
Author(s):  
U. Ferreira ◽  
N. Rodrigues Netto ◽  
R. Lucena
Keyword(s):  
Colonic Reservoir

Total rectal resection and colo-anal anastomosis with colonic reservoir for low rectal cancer

1994 ◽  
Vol 9 (2) ◽  
pp. 82-86 ◽  
Author(s):  
E. Leo ◽  
F. Belli ◽  
M. T. Baldini ◽  
M. Vitellaro ◽  
L. Mascheroni ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Rectal Resection ◽  
Low Rectal Cancer ◽  
Anal Anastomosis ◽  
Colonic Reservoir

Resection and colo-anal anastomosis with colonic reservoir for rectal carcinoma

1986 ◽  
Vol 73 (2) ◽  
pp. 139-141 ◽  
Author(s):  
R. Parc ◽  
E. Tiret ◽  
P. Frileux ◽  
E. Moszkowski ◽  
J. Loygue
Keyword(s):  
Rectal Carcinoma ◽  
Anal Anastomosis ◽  
Colonic Reservoir
Sign in / Sign up

Export Citation Format

Share Document